EQT Life Sciences and Sanofi Ventures led a $135m Series B round in SpliceBio.

EQT Life Sciences, an investment firm, and Sanofi Ventures, the corporate venture capital arm of Sanofi, led a $135m Series B round in SpliceBio, a Spanish biotech company. “This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology, and beyond. The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today. We are building a company positioned to lead the next wave of genetic medicines,” Miquel Vila-Perelló, SpliceBio Chief Executive Officer and Co-Founder.